Panzyga (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Panzyga, is an Immunoglobulin presented as a unknown/intravenous infusion for intravenous use. It replaces deficient antibodies and is used in primary immunodeficiency disorders and certain immune‑mediated conditions in both children and adults.

GNH USA supplies Panzyga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Panzyga is an immunoglobulin therapy that acts on disorders of the immune system requiring antibody replacement. - Primary immunodeficiency diseases: provides functional antibodies to reduce infection risk. - Chronic immune thrombocytopenia (ITP): helps raise platelet counts in refractory cases. - Multifactorial immune‑mediated neuropathies: may improve neurological function and pain relief. - Secondary hypogammaglobulinemia after hematopoietic stem cell transplantation: supports immune reconstitution. - Certain autoimmune hemolytic anemias: contributes to hemolysis control. - Off‑label use in some viral infections where antibody support is beneficial.

Adverse reactions to Panzyga are reported across a range of frequencies.

Common Side Effects: - Headache: mild to moderate intensity. - Fever or chills: transient during or after infusion. - Nausea or vomiting: generally mild. - Fatigue or malaise: common post‑infusion. - Injection site erythema or swelling: localized reaction. - Hypertension: temporary rise in blood pressure.

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity: immediate medical attention required. - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Acute renal failure: especially with rapid infusion rates. - Aseptic meningitis: rare neurologic complication. - Hemolytic transfusion reactions: immune‑mediated red cell destruction. - Severe hemolysis or hemolytic anemia: requires urgent care.

When using Panzyga, clinicians should consider several safety measures. - Infusion rate: adjust to patient tolerance to minimise reactions. - Pre‑medication: antihistamines or steroids may be given to reduce hypersensitivity. - Renal function: monitor creatinine and urine output, especially in high‑risk patients. - Cardiovascular status: observe for hypertension or fluid overload. - Thrombotic risk: assess history of clotting disorders before therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Panzyga may interact with other agents, influencing safety or efficacy.

Major Interactions (Avoid): - Live vaccines: concurrent use can diminish vaccine efficacy and increase infection risk. - High‑dose aspirin or NSAIDs: may raise bleeding risk when combined with immunoglobulin‑induced platelet changes.

Moderate Interactions (Monitor Closely): - Corticosteroids: may augment immunosuppressive effects, requiring dose adjustment. - Anticoagulants (e.g., warfarin): monitor INR closely as immunoglobulin can affect coagulation parameters. - Diuretics: fluid shifts during infusion may potentiate electrolyte disturbances. - ACE inhibitors: watch for additive hypertension. - Rituximab: combined immunosuppression may increase infection susceptibility.